Binnopharm Group, a pharmaceutical manufacturer, has registered levofloxacin hemihydrate production and released the first 100 kg of the pharmaceutical substance, which is the main active component for Levofoxacin antibiotic, the company reports.
“The Russian Ministry of Health has included this drug in the COVID-19 treatment protocols. The substance produced by the Group is included in the registration certificate of the drug manufactured at the Binnopharm Group site in Kurgan: now the company is able to perform the whole cycle of this medicine production. By the end of 2021, the production of Levofloxacin will also be localized at the facility in Obolensk village of the Moscow Region,” the report says.
“Levofloxacin is an antibiotic used for the prevention and treatment of COVID-19. In order to meet the sharply increased demand for this drug from patients and medical institutions, we increased the production by 3.3 times in 2020, which meant that the workload of our production facilities in Kurgan reached the capacity limit,” says Rustem Muratov, General Director of Binnopharm Group. “Taking into account the high social significance of the drug and the fact that we are the largest manufacturer of the antibiotic, it was decided to organize its production at the production site of OAO Sintez from our own pharmaceutical substances.”
According to AlphaRM, in 2019, Levofloxacin sales in Russia amounted to 13.9 million packages, and in 2020, the consumption of this antibiotic increased to 30 million packages.
